Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Esperion Therapeutics is a biopharmaceutical company focused on developing and commercializing oral, non-statin medicines to lower LDL cholesterol and reduce cardiovascular risk. Its flagship products, NEXLETOL and NEXLIZET, target patients with hyperlipidemia, statin intolerance, or high cardiovascular risk. The company leverages partnerships, clinical trials, and a strong pipeline to address unmet medical needs in cardiovascular disease prevention.
This description was generated via AI from an annual report. Updated about 1 year ago.